04 Sept 2015
Adding the mineralocorticoid receptor antagonist finerenone to standard renin-angiotensin system (RAS) blockade decreased albuminuria and improved the urinary albumin/creatinine ratio in an industry-sponsored phase IIB clinical trial of diabetic nephropathy, according to a report published The Journal of the American Medical Association.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024